Lexaria Bioscience Corp. LXRP Archives - Page 22 of 27

ThursdayJan 25, 2018 4:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids Uplisted to OTCQX® Best Market Licensing model generates profit margins in excess of 90 percent A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://ibn.fm/v4WGq). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly…

WednesdayJan 24, 2018 12:19 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio

Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://ibn.fm/iaAZ9), the global API market is anticipated to reach $239.8 billion by 2025, with…

TuesdayJan 23, 2018 2:07 pm

Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing

Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs Active pharmaceutical ingredient market expected to exceed $239 billion by 2025 19 patent applications filed in U.S. and internationally encompassing 44 countries Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million…

FridayJan 19, 2018 1:24 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) demonstrated several transformative developments in 2017. The company’s Intellectual Property (“IP”) was strengthened, it was awarded broad patents, and it secured finances during the year. Now, Lexaria is concentrating on making 2018 an even more fruitful year. An article discussing the company’s recent progress reads: “The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit…

ThursdayJan 11, 2018 3:34 pm

2017 was a Transformative Year for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Lexaria’s CEO posts end of 2017 summary Multiple transformative developments – IP strengthened, broad patents awarded, finances secured Foundation for the future established – multiple opportunities on horizon If the past is any prologue, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) should have a break out year in 2018. Lexaria’s CEO, Chris Bunka, recently posted ‘LXRP CEO’s End of 2017 Summary’. It was a transformative year with multiple accomplishments that should establish a strong foundation for the future. Lexaria Bioscience has developed, patented and commercialized a cost-effective lipophilic delivery technology, DehydraTECH™, to enhance the performance of beneficial compounds in ingestible…

MondayJan 08, 2018 1:34 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Recaps 2017 Highlights

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced the release of a 2017 year-end summary penned by CEO Chris Bunka. The release highlights what Bunka refers to as Lexaria’s “busiest and most productive” year to date, including details about the company’s progress toward strengthening its balance sheet, ongoing research and development efforts related to its patented DehydraTECH™ absorption and palatability enhancing technology, its preparations for increased demand in both Californian and Canadian markets and its ongoing efforts to strengthen its intellectual property portfolio. Bunka…

ThursdayJan 04, 2018 12:35 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Trading on OTCQX Best Market

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, this morning announced that Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has qualified to trade on the OTCQX® Best Market. Subsequently, Lexaria has upgraded from the OTCQB® Venture Market, beginning today. “Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria…

WednesdayJan 03, 2018 12:49 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Highlights Hidden Value of Wide-ranging DehydraTECH™ Patent

Based in Kelowna, British Columbia, Canada, food bioscience company Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is a technology disruptor for edible CBD. An article discussing this reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://dtn.fm/cH5lL) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the…

TuesdayJan 02, 2018 3:36 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Marks Milestone with Patent Approval

LXRP awarded broad-ranging U.S. patent for novel DehydraTECH™ drug delivery system Already scientifically proven to increase efficacy of cannabinoids IP protection opens myriad business opportunities Food bioscience company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) just hit another major milestone in the disruption of drug delivery and administration. With 19 international patent applications filed encompassing 44 countries, Lexaria recently announced its reception of a broad-ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients (http://dtn.fm/Dp5EG). The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and…

WednesdayDec 27, 2017 2:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018

DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty), as well as national filings in 44 countries Company has diverse revenue streams, including out-licensing its technology to third parties with fees ranging from five to 10 percent of gross sales, as well as sales of…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP